.png)
Despite each patient having a unique cancer profile, treatment selection relies on general criteria (one-size-fits-all).
It is estimated that cancer drugs are generally ineffective in a ~ 75% of patients.
.svg)
.svg)
In vitro models based on tissue specimens or organoids fail to accurately replicate the dynamic physiological microenvironment, crucial for the successful prediction of treatment outcomes.
Pre-Cure transforms cancer treatment selection powered by advanced customized microfluidic tumor-on-a-chip technology.
In Pre-cure “organ-on-a-chip” becomes “patient-on-a-chip” where the entire clinical journey is reflected to provide accurate individual therapy predictions.